Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo


Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Search Cancer Clinical Trials

Search our clinical trials database by disease type, trial number, location or phase. Must press "Go" to activate search.  

ECOG E3F05   |   CC869
Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

Main Campus
Phase 3
Temozolomide (SCH 52365)

Contact Information
Cancer Answer Line


8:00 am - 4:30 pm, Monday - Friday


Primary Objectives

  1. To determine whether the addition of temozolomide to fractionated radiotherapy improves the progression-free survival (PFS) of patients requiring treatment for low grade gliomas.
  2. To determine whether the addition of temozolomide to fractionated radiotherapy improves the median overall survival (OS) of patients with low-grade gliomas requiring treatment.

Secondary Objectives

  1. To determine whether combination therapy with temozolomide and radiotherapy improves or maintains cognition and quality of life (QOL) compared to radiotherapy alone.
  2. To compare the severe or worse toxicities (≥ grade 3) of patients receiving radiation therapy alone or radiation therapy plus temozolomide chemotherapy.
  3. To assess the impact of the presence or absence of 1p and 19q deletion on PFS and OS, and to determine the impact of 1p and 19q status on PFS and OS in patients receiving chemotherapy.
  4. To create a tumor and tissue bank, including plasma and germ line DNA, within the ECOG Pathology Coordinating Office (PCO).

Inclusion Criteria


  1. Age ≥ 18 years.
  2. Tumors must be supratentorially located.
  3. Pathological diagnosis of astrocytoma grade 2, oligodendroglioma grade 2, or oligoastrocytoma grade 2 (mixed glioma containing astrocytoma and oligodendroglioma). Pilocytic astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma, or dysembryoplastic neuroepithelial tumors are not eligible. NOTE: If the pathology from multiple procedures supports the diagnosis of a brain tumor, the qualifying pathology of grade 2 astrocytoma, oligodendroglioma, or oligoastrocytoma must be the most recent pathological diagnosis, and a pathological diagnosis of a grade 3 or grade 4 glioma must not have been made at any time.
  4. Patients must have paraffin-embedded tumor specimen available for submission for confirmation of pathological diagnosis and determination of 1p/19q deletion status. NOTE: It is recommended that patients not be Pre-registered until the required tumor specimens are on hand and ready for submission as outlined in Section 10. If submission of tissue will be submitted more than 5 working days after pre-registration, immediately notify the Mayo Clinic Cytogenetics Laboratory via email:
  5. The patient must currently have at least one of the following:
    • Uncontrolled symptoms, defined as any of the below:
      • Headaches associated with mass effect
      • Uncontrolled seizures despite 2 different antiepileptic drug regimens (i.e., 2 antiepileptic drugs tested either sequentially or in combination)
      • Focal neurological symptoms
      • Cognitive symptoms or deficits
    • Tumor progression by serial MRIs, defined as any of the below:
      • New or progressive enhancement
      • New or progressive T2 or FLAIR signal abnormality
    • Age ≥ 40 years. NOTE: Patients aged less than 40 whose only symptom of low-grade glioma is seizures that are well-controlled on antiepileptic drugs, and who have no evidence of radiographic progression, are ineligible. The rationale is that such patients have a relatively good prognosis and are often managed expectantly with observation. Excluding such patients will maintain similar eligibility requirements with the ongoing EORTC trial comparing radiation to temozolomide for patients with low-grade gliomas.
  6. Patient must be able to undergo MRI with and without contrast. Patients who are unable to undergo MRI are ineligible.
  7. MRI and chest x-ray within 6 weeks prior to pre-registration. A postoperative MRI is required for all patients who underwent open biopsy, or resection, but is not mandatory following stereotactic biopsy.
  8. No previous radiation, cytotoxic chemotherapy, radio surgery, or investigational treatment directed at the brain tumor at any time. No limit on number of previous surgical procedures of this tumor.
  9. No previous radiation treatment to the head (unless the ports for that radiation entirely excluded the brain) for any condition.
  10. Karnofsky performance status ≥ 60%.
  11. No other diagnosed malignancy (except non-melanoma skin cancer or cervical carcinoma in situ, which are allowable), unless the patient has been disease-free for at least 5 years.
  12. No medical disorder that increases risks of radiation or TMZ chemotherapy. No uncontrolled infection. No known positivity for human immunodeficiency virus (HIV), as temozolomide is known to cause immunosuppression and increase risk of opportunistic infection. No other disorder limiting expected survival to < 5 years.
  13. Patients who have undergone gross total resection and have no detectable residual disease are eligible.

Randomization (Step 1)

  1. Eligibility per pathologic diagnosis confirmed by central review and 1p/19q deletion status assessment have been received from the central reviewers.
  2. Must be able to start treatment with RT within 2 weeks or 10 working days at a qualified center (to be defined by the Radiation Oncology chair) and to start TMZ prescribed at a participating center within 2 weeks or 10 working days of randomization.
  3. CBC requirements within 14 days prior to randomization:
    • White blood count (WBC) ≥ 3,000 /mm³
    • Absolute neutrophil count (ANC) ≥ 1,500 /mm³
    • Platelets ≥ 100,000 /mm³
    • Hematocrit ≥ 30%
  4. Chemistry requirements within 14 days prior to randomization:
    • Bilirubin ≤ 2 x upper limit of normal (ULN)
    • AST ≤ 3 x ULN (SGOT)
    • Creatinine ≤ 2.0 x ULN
    • ALT ≤ 3 x ULN (SGPT)
  5. Women must not be pregnant or breast-feeding due to known and potential teratogenic effects of radiotherapy and temozolomide and the uncertain safety of temozolomide in lactation. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy.
  6. Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception.
  7. Patient must be at least two weeks post any brain surgery (whether stereotactic biopsy, open biopsy or resection) at the time of randomization.

Exclusion Criteria
Exclusion Criteria Not Available

Download the Cleveland Clinic Cancer Clinical Trials App

clinical trials app logo

Stay up to date on Cleveland Clinic’s more than 200 active clinical trials for cancer patients. Our free Cancer Clinical Trials app is available for Apple and Android devices.

With this app, you can:

The app also includes contacts for patient resources, financial services information, support groups and treatment guides.

Cleveland Clinic Cancer Trials - Cleveland Clinic Innovations
Android app on Google Play

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2015 Cleveland Clinic. All rights reserved.